The Association of Cell Surface Fibromodulin Expression and Bladder Carcinoma Anti-FMOD induce apoptosis in bladder cancer
Background: Fibromodulin (FMOD) is a secretory protein which is considered a major component of extracellular matrix. Its dysregulation in different types of cancer implies it as a promising target for cancer therapy. Within the scope of its rather wide expression in different tumors, we studied expression of FMOD and effect of anti-FMOD antibody in bladder cancer cells in order to identify new target for diagnostic and therapeutic interventions. We report here for the first time the expression of FMOD in bladder cancer cell lines in comparison to the normal cell line and tissues.
Methods: A peptide-based produced anti-FMOD murine monoclonal antibody (mAb) (clone 2C2-A1) was applied for evaluation of FMOD expression in bladder cancer and normal tissues by immunohistochemistry (IHC) staining. Furthermore, the expression of FMOD was examined in human bladder cell lines, 5637 and EJ138, as well as a non-cancerous human cell line, human fetal foreskin fibroblast (HFFF), by immunocytochemistry (ICC) and flow cytometry. The apoptosis induction of anti-FMOD mAb was also evaluated in bladder cancer cells.
Results: IHC and ICC analyses revealed that the qualitative expression of FMOD in bladder cancer tissues and cell lines is higher than in normal tissues and cell lines. Flow cytometry analyses revealed that 2C2-A1 mAb could recognize FMOD expression in 84.05 ± 1.85%, 46.1 ± .4% , and 2.56 ± 1.26% of 5637, EJ138, and HFFF cells, respectively. An effective apoptosis induction was detected in 5637 and EJ138 cells with no significant effect on HFFF cell.
Conclusion: To our knowledge, this is for the first time reporting surface expression of FMOD in bladder cancer. This significant surface expression of FMOD in bladder cancer with no expression in normal bladder tissues and the capacity of inducing apoptosis through directed targeting of FMOD with specific monoclonal antibody might candidates FMOD as a diagnostic marker as well as a potential immunotargeting with monoclonal antibody.
- Bladder cancer, Fibromodulin, Monoclonal antibody, Targeted therapy
How to Cite
2. He H, Han C, Hao L, Zang G. ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysis. Oncology letters. 2016;12:83-8.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
4. DeGeorge KC, Holt HR, Hodges SC. Bladder Cancer: Diagnosis and Treatment. Am Fam Physician. 2017;96:507-14.
5. Bayat AA, Sadeghi N, Fatemi R, et al. Monoclonal Antibody Against ROR1 Induces Apoptosis in Human Bladder Carcinoma Cells. Avicenna Journal of Medical Biotechnology. 2020;12:165-71.
6. Endo M, Minami Y. Diverse roles for the ror‐family receptor tyrosine kinases in neurons and glial cells during development and repair of the nervous system. Developmental Dynamics. 2018;247:24-32.
7. Nielsen MS, Madsen P, Christensen EI, et al. The sortilin cytoplasmic tail conveys Golgi–endosome transport and binds the VHS domain of the GGA2 sorting protein. The EMBO journal. 2001;20:2180-90.
8. Oldberg A, Antonsson P, Lindblom K, Heinegård D. A collagen-binding 59-kd protein (fibromodulin) is structurally related to the small interstitial proteoglycans PG-S1 and PG-S2 (decorin). Embo j. 1989;8:2601-4.
9. Farahi L, Ghaemimanesh F, Milani S, et al. Monoclonal and polyclonal antibodies specific to human fibromodulin. Iranian journal of biotechnology. 2019;17.
10. Choudhury A, Derkow K, Daneshmanesh AH, et al. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. British journal of haematology. 2010;151:327-35.
11. Antonsson P, Heinegard D, Oldberg A. Structure and deduced amino acid sequence of the human fibromodulin gene. Biochim Biophys Acta. 1993;1174:204-6.
12. Farahi L, Ghaemimanesh F, Milani S, et al. GPI-anchored fibromodulin as a novel target in chronic lymphocytic leukemia: diagnostic and therapeutic implications. Iranian Journal of Immunology. 2019;16:127-41.
13. Pourhanifeh MH, Mohammadi R, Noruzi S, et al. The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy. Cancer cell international. 2019;19:157.
14. Choudhury A, Derkow K, Daneshmanesh AH, et al. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br J Haematol. 2010;151:327-35.
15. Hassan DAE-h, Samy RM, Abd-Elrahim OT, Salib CS. Study of fibromodulin gene expression in B-cell chronic lymphocytic leukemia. Journal of the Egyptian National Cancer Institute. 2011;23:11-5.
16. Bettin A, Reyes I, Reyes N. Gene expression profiling of prostate cancer-associated genes identifies fibromodulin as potential novel biomarker for prostate cancer. Int J Biol Markers. 2016;31:e153-62.
17. Farahi L, Ghaemimanesh F, Milani S, et al. Monoclonal and Polyclonal Antibodies Specific to Human Fibromodulin. Iran J Biotechnol. 2019;17:e2277.
18. Pourhanifeh MH, Mohammadi R, Noruzi S, et al. The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy. Cancer Cell Int. 2019;19:157.
19. Kuhlmann L, Cummins E, Samudio I, Kislinger T. Cell-surface proteomics for the identification of novel therapeutic targets in cancer. Expert Rev Proteomics. 2018;15:259-75.
20. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018;834:188-96.
21. Bayat AA, Ghods R, Shabani M, et al. Production and characterization of monoclonal antibodies against human prostate specific antigen. Avicenna journal of medical biotechnology. 2015;7:2.
22. Bayat AA, Yeganeh O, Ghods R, et al. Production and characterization of a murine monoclonal antibody against human ferritin. Avicenna Journal of Medical Biotechnology. 2013;5:212.
23. Tsai Y-C, Tsai T-H, Chang C-P, Chen S-F, Lee Y-M, Shyue S-K. Linear correlation between average fluorescence intensity of green fluorescent protein and the multiplicity of infection of recombinant adenovirus. Journal of biomedical science. 2015;22:31.
24. Norouzi S, Norouzi M, Amini M, et al. Two COX-2 inhibitors induce apoptosis in human erythroleukemia K562cells by modulating NF-κB and FHC pathways. DARU Journal of Pharmaceutical Sciences. 2016;24:1.
25. Reyes N, Benedetti I, Bettin A, Rebollo J, Geliebter J. The small leucine rich proteoglycan fibromodulin is overexpressed in human prostate epithelial cancer cell lines in culture and human prostate cancer tissue. Cancer Biomarkers. 2016;16:191-202.
26. Filipe EC, Chitty JL, Cox TR. Charting the unexplored extracellular matrix in cancer. Int J Exp Pathol. 2018;99:58-76.
27. Brown Y, Hua S, Tanwar PS. Extracellular matrix-mediated regulation of cancer stem cells and chemoresistance. Int J Biochem Cell Biol. 2019;109:90-104.
28. Henke E, Nandigama R, Ergün S. Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Front Mol Biosci. 2019;6:160.
29. Ismael R, Tiwari R, Geliebter J, Reyes N. DNA microarray analysis reveals metastasis-associated genes in rat prostate cancer cell lines. Biomedica. 2007;27:190-203.
30. Reyes N, Benedetti I, Bettin A, Rebollo J, Geliebter J. The small leucine rich proteoglycan fibromodulin is overexpressed in human prostate epithelial cancer cell lines in culture and human prostate cancer tissue. Cancer Biomark. 2016;16:191-202.
31. Mikaelsson E, Danesh-Manesh AH, Lüppert A, et al. Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood. 2005;105:4828-35.
32. Bettin A, Reyes I, Reyes N. Gene Expression Profiling of Prostate Cancer–Associated Genes Identifies Fibromodulin as Potential Novel Biomarker for Prostate Cancer. The International journal of biological markers. 2016;31:153-62.
33. Colin C, Baeza N, Bartoli C, et al. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene. 2006;25:2818-26.
34. Cabello MJ, Grau L, Franco N, et al. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J Mol Diagn. 2011;13:29-40.
35. Luo Y, Zhu YT, Ma LL, et al. Characteristics of bladder transitional cell carcinoma with E-cadherin and N-cadherin double-negative expression. Oncol Lett. 2016;12:530-6.
36. Ramesh S, Wildey GM, Howe PH. Transforming growth factor β (TGFβ)-induced apoptosis: the rise and fall of Bim. Cell Cycle. 2009;8:11-7.
37. Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate-and high-risk non–muscle-invasive bladder cancer. European urology. 2016;69:1046-52.
38. Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non–muscle-invasive bladder cancer. European urology. 2009;56:247-56.
39. Zhu CZ, Ting HN, Ng KH, Ong TA. A review on the accuracy of bladder cancer detection methods. J Cancer. 2019;10:4038-44.
40. Farahi L, Ghaemimanesh F, Milani S, et al. Anchored Fibromodulin as a Novel Target in Chronic Lymphocytic Leukemia: Diagnostic and Therapeutic Implications. Iran J Immunol. 2019;16:127-41.
- Abstract Viewed: 0 times
- Just Accepted/6461 Downloaded: 0 times